While in vivo CAR-T therapies eliminate complex ex vivo manufacturing, they introduce a new critical variable: the patient's own immune system. The therapy's efficacy relies on modifying T-cells within the body, but each patient's immune status is different, especially after prior treatments. This makes optimizing and standardizing the dose a significant challenge compared to engineered cell therapies.

An investigational in vivo CAR-T therapy uses viral particles infused directly into the patient to convert their T-cells into CAR-T cells. This approach eliminates the complex steps of apheresis, lymphodepletion, and ex vivo manufacturing, effectively creating an off-the-shelf product that becomes an autologous treatment inside the body.

Many early cell therapies failed due to the impractical cost and complexity of individual manufacturing for each patient. Companies now succeeding are developing "off-the-shelf" treatments that don't require patient matching or immune suppression, creating a more scalable and commercially viable model similar to traditional drugs.

While scientifically novel, the primary advantage of in vivo CAR-T therapy is its potential to overcome the significant logistical barriers of traditional CAR-T. By simplifying the process to a single injection, it could democratize access for patients far from specialized academic medical centers.

The next frontier in cellular therapy is in-vivo CAR-T, where a gene for the CAR receptor is delivered into the patient (e.g., via mRNA lipid nanoparticles) to create CAR-T cells internally. This eliminates the complex and costly external manufacturing process, potentially creating an 'off-the-shelf' CAR-T therapy.

Despite exciting early efficacy data for in vivo CAR-T therapies, the modality's future hinges on the critical unanswered question of durability. How long the therapeutic effects last, for which there is little data, will ultimately determine its clinical viability and applications in cancer versus autoimmune diseases.

Early data from an in vivo CAR-T therapy suggests a paradigm shift is possible. By engineering T-cells directly inside the patient with a simple infusion, this approach could eliminate the need for leukapheresis and external manufacturing, completely disrupting the current cell therapy model.

The high capital cost of autologous CAR-T manufacturing creates a moat for incumbents like Legend. Consequently, future investment will likely flow towards next-generation platforms like in vivo CAR-T, which promises an "off-the-shelf" solution that eliminates complex external manufacturing and patient pre-conditioning.

The ideal future for personalized cell therapies involves decentralized manufacturing using mobile units at the point of care, like a hospital. This model, which Cellino is pioneering with Mass General Hospital, eliminates complex logistics, reduces costs, and broadens patient access beyond major urban centers to rural areas.